Skip to content

Gastrointestinal Microbiota in Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin

The Human Gastrointestinal Tract Microbiota in the Setting of Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin.

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01322386
Acronym
PSC
Enrollment
32
Registered
2011-03-24
Start date
2007-05-31
Completion date
2012-01-31
Last updated
2016-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biliary Atresia, Primary Sclerosing Cholangitis

Keywords

PSC, BA

Brief summary

The goals of the proposed work are two fold: Firstly, to see if the antibiotic vancomycin may be used for the early treatment of Biliary Atresia (BA) and Primary Sclerosing Cholangitis (PSC). The investigators hope to learn what effect Vancomycin has on the bacteria that are present in stool, body fluid or intestinal tissue on someone who has BA and PSC and if so by what mechanism. Secondly, the investigators hope to learn to characterize human intestinal microbial communities (microbiome: the collection or collectivity of microorganisms) using molecular methods, examine the mechanisms of interaction between host and microbiome using genomic approaches, and determine how the microbiome both preserves local health and promotes pathology. The investigators will focus on primary sclerosing cholangitis, biliary atresia, as well as states of health. The composition of the associated microbiome will be assessed based on ribosomal DNA and RNA sequences, and attention will be given to richness (diversity), evenness (relative abundance), and variation with respect to time, person, and anatomic niche. Host response at the adjacent mucosal surface will be assessed based on genome-wide gene expression patterns.

Detailed description

As many as 55 subjects (35 with BA or PSC and 20 Controls) will be involved. We are also recruiting 20 adult patients with either BA, or PSC. The patients will be recruited from Lucile Children's Hospital, Stanford Medical Center, and Stanford Redwood City Campus such as patients with primary sclerosing cholangitis, biliary atresia or other intestinal disorders for whom upper or lower endoscopy is indicated for routine medical management. There may be some participants who are over 18 years of age although the vast majority will be under 18. Vancomycin therapy will be administered to the BA patients (4 weeks)and PSC patients. The PSC patient blood tests would now be done at various intervals: before starting the Vancomycin; every month until their Liver Function Tests are normalized; after their Liver Function Tests are normalized; before stopping the Vancomycin and after they are off the Vancomycin at month 1,3,6,12,and 24. Fecal samples will be taken. In addition, patients who will already be undergoing either upper or lower intestinal endoscopy for routine diagnostic or therapeutic purposes will be asked to agree to endoscopic mucosal brushings in addition to mucosal biopsies. Some will be patients with a diagnosis of primary sclerosing cholangitis, biliary atresia, or other intestinal disorders for whom upper or lower endoscopy is indicated for routine medical management. Others will have lower intestinal findings (polyps) or complaints (e.g. occult blood in stool), or upper intestinal findings (dyspepsia, reflux), and will be undergoing lower endoscopy (colonoscopy) or upper endoscopy for routine medical management. Up to 2 biopsies will be obtained from the gastric mucosa and of as many as 6 intestinal sites from each patient. In addition the following brushings will be taken: 2 from mid-esophagus, 2 from lesser curvature of the stomach, 2 from the second portion of the duodenum near the ampulla. 2 from the jejunum 5 cm from the Ligament of Trietz, and 2 from the ileum 10 cm from the ileocecal valve. We will also obtain brushing from the tongue. A sample of saliva will be taken. Fecal specimens will also be collected just prior to bowel preparation for endoscopy/colonoscopy. If the BA patient is already having a Kasai portoenterostomy, done to remove the diseased bile ducts, we would like to take a biopsy of the bile duct. If the patient has a liver biopsy clinically done we would like to keep a 2mm section of it. If the patient has an intraoperative cholangiogram to evaluate the bile ducts we will collect 2.5 cc. of bile fluid. With regards to the controls, who have other intestinal disorders and are also having clinical endoscopies done, we would request a midesophagus biopsy; a biopsy from the antrum and 2 biopsies from the 4th portion of the duodenum. Cell brushings will be taken from the following areas: 2 from mid-esophagus, 2 from lesser curvature of the stomach, 2 from the second portion of the duodenum near the ampulla. 2 from the jejunum 5 cm from the Ligament of Trietz, and 2 from the ileum 10 cm from the ileocecal valve. We will also obtain brushing from the tongue. A sample of saliva will be taken. If the patient is having a colonoscopy done as part of their clinical care we would request a biopsy from the ileum, cecum, and transverse descending rectum. We would also ask for a saliva sample. The blood tests would now be done at various intervals: before starting the Vancomycin; every month until their Liver Funtion Tests are normalized; after their Liver Function Tests are normalized; before stopping the Vancomycin and after they are off the Vancomycin at month 1,3,6,12 and 24.

Interventions

DRUGVancomycin

Oral 50mg/Kg per day up to maximum of 1500 mg a day for three months.

Sponsors

Stanford University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Months to 20 Years
Healthy volunteers
No

Inclusion criteria

* Clinical diagnosis of biliary atresia or primary sclerosing cholangitis. * Clinical controls who are undergoing upper endoscopy or colonoscopy and do not have biliary atresia or primary sclerosing cholangitis. * Subjects who have been on oral vancomycin for 1 year for biliary atresia or -

Exclusion criteria

* Patients that have taken antibiotics within the last 3 month will be excluded as this will alter the original bacterial flora.

Design outcomes

Primary

MeasureTime frameDescription
Determine the Benefit of Oral Vancomycin Therapy for Primary Sclerosing Cholangitis and Biliary AtresiaWithin 3 months of therapyDetermine the benefit of oral vancomycin therapy for Primary Sclerosing Cholangitis and Biliary Atresia through improvement of Liver function tests (LFTs) within 3 months of initiating therapy. In addition for PSC, we looked at 25% reduction of abnormal ALT & GGT, reduction in biliary strictures and beading, and reduction of inflammation in liver biopsies and colon biopsies.

Participant flow

Recruitment details

Participants were recruited by the Physician and research team at Lucille Packard and Stanford Hospital and Clinics from 2007 - 2010. The first participant was enrolled in November 2008, and the last participant was enrolled in October 2010.

Pre-assignment details

11 PSC patients whose consent to participate was obtained did not participate in the Study.

Participants by arm

ArmCount
Oral Vancomycin-BIliary Atresia
Enrolled- 10, Participated - 10,Completed - 10 (Based on Annual Progress Report in Oct 2010)
10
Oral Vancomycin - PSC
Enrolled- 11, Participated - 10 ,Completed - 9 (Based on Annual Progress Report in Oct 2010)
11
Total21

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyPhysician Decision01
Overall StudyProtocol Violation01

Baseline characteristics

CharacteristicTotalOral Vancomycin - PSCOral Vancomycin-BIliary Atresia
Age, Customized
12-16 years
6 participants6 participants0 participants
Age, Customized
1-3 months
10 participants0 participants10 participants
Age, Customized
2-4 years
3 participants3 participants0 participants
Age, Customized
9-11 years
2 participants2 participants0 participants
Race/Ethnicity, Customized
African American
2 participants0 participants2 participants
Race/Ethnicity, Customized
Caucasian
15 participants10 participants5 participants
Race/Ethnicity, Customized
Hispanic
4 participants1 participants3 participants
Sex: Female, Male
Female
11 Participants5 Participants6 Participants
Sex: Female, Male
Male
10 Participants6 Participants4 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 21
serious
Total, serious adverse events
1 / 21

Outcome results

Primary

Determine the Benefit of Oral Vancomycin Therapy for Primary Sclerosing Cholangitis and Biliary Atresia

Determine the benefit of oral vancomycin therapy for Primary Sclerosing Cholangitis and Biliary Atresia through improvement of Liver function tests (LFTs) within 3 months of initiating therapy. In addition for PSC, we looked at 25% reduction of abnormal ALT & GGT, reduction in biliary strictures and beading, and reduction of inflammation in liver biopsies and colon biopsies.

Time frame: Within 3 months of therapy

Population: Ten BA participants had surgery (Kasai portoenterostomyprocedure) at 1 week before starting the Vancomycin so we could not determine if they benefited from the therapy. On oral vancomycin, 9 PSC patients had improvement of LFTs, 8 had improvement of liver biopsies and/or MRI, and colon biopsies,and 1 pt. refused to have these additional studies.

ArmMeasureGroupValue (NUMBER)
Liver Blood TestDetermine the Benefit of Oral Vancomycin Therapy for Primary Sclerosing Cholangitis and Biliary AtresiaBA (n=10,0,0,0,0)10 participants
Liver Blood TestDetermine the Benefit of Oral Vancomycin Therapy for Primary Sclerosing Cholangitis and Biliary AtresiaPSC (n=9,7,4,8,8)9 participants
MRI / MRCPDetermine the Benefit of Oral Vancomycin Therapy for Primary Sclerosing Cholangitis and Biliary AtresiaBA (n=10,0,0,0,0)0 participants
MRI / MRCPDetermine the Benefit of Oral Vancomycin Therapy for Primary Sclerosing Cholangitis and Biliary AtresiaPSC (n=9,7,4,8,8)7 participants
Liver BiopsyDetermine the Benefit of Oral Vancomycin Therapy for Primary Sclerosing Cholangitis and Biliary AtresiaBA (n=10,0,0,0,0)0 participants
Liver BiopsyDetermine the Benefit of Oral Vancomycin Therapy for Primary Sclerosing Cholangitis and Biliary AtresiaPSC (n=9,7,4,8,8)4 participants
Colon BiopsiesDetermine the Benefit of Oral Vancomycin Therapy for Primary Sclerosing Cholangitis and Biliary AtresiaPSC (n=9,7,4,8,8)8 participants
Colon BiopsiesDetermine the Benefit of Oral Vancomycin Therapy for Primary Sclerosing Cholangitis and Biliary AtresiaBA (n=10,0,0,0,0)0 participants
Liver Biopsy and/or MRIDetermine the Benefit of Oral Vancomycin Therapy for Primary Sclerosing Cholangitis and Biliary AtresiaBA (n=10,0,0,0,0)0 participants
Liver Biopsy and/or MRIDetermine the Benefit of Oral Vancomycin Therapy for Primary Sclerosing Cholangitis and Biliary AtresiaPSC (n=9,7,4,8,8)8 participants

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026